Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Amgen, Inc.    AMGN

 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
03/22/2017 03/23/2017 03/24/2017 03/27/2017 03/28/2017 Date
167.45(c) 166.04(c) 165.74(c) 164.91(c) 164.69 Last
5 070 374 4 432 154 3 175 587 4 733 979 2 493 654 Volume
+0.36% -0.84% -0.18% -0.50% -0.13% Change
More quotes
Financials ($)
Sales 2017 23 012 M
EBIT 2017 11 705 M
Net income 2017 8 097 M
Finance 2017 1 921 M
Yield 2017 2,74%
Sales 2018 23 229 M
EBIT 2018 11 961 M
Net income 2018 8 205 M
Finance 2018 14 866 M
Yield 2018 2,96%
P/E ratio 2017 15,07
P/E ratio 2018 14,57
EV / Sales2017 5,19x
EV / Sales2018 4,59x
Capitalization 121 448 M
More Financials
Company
Amgen, Inc. is a biotechnology medicines company, which discovers, develops, manufactures and markets medicines for grievous illnesses.It focuses on human therapeutics and concentrates on innovating novel medicines based on advances in cellular and molecular biology.It markets recombinant protein... 
More about the company
Surperformance© ratings of Amgen, Inc.
Trading Rating : Investor Rating :
More Ratings
Latest news on AMGEN, INC.
03:01p AMGEN : Awards Three Golden Tickets for LabCentral Residency
04:02a AMGEN : announces layoffs and relocations in Thousand Oaks
03/24 AMGEN, INC. (NASDAQ : AMGN) Amgevita Approved By The European Commission Giving ..
03/23 AMGEN : European Commission Approves AMGEVITA(TM) (Biosimilar Adalimumab) For Th..
03/21 AMGEN INC. : (AMGN) Sank To A 1-Month Low After Repatha Study
03/20 ESPERION THERAPEUTICS INC (NASDAQ : ESPR): Get It While It’s Cheap
03/19 AMGEN : Analyses Of PCSK9 Inhibitor Prescription Rejection Rates Demonstrate Sig..
03/18 AMGEN : Lowering LDL Levels With Repatha® (Evolocumab) Did Not Adversely Affect ..
03/18DJAMGEN : Repatha Study Shows Reduced Risk of Heart Attack, Stroke -- 3rd Update
03/17 Amgen and AXT slump while Adobe and Tiffany advance
More news
Sector news : Bio Therapeutic Drugs
03/17DJAmgen's Repatha Study Shows Reduced Risk of Heart Attack, Stroke -- Update
03/17DJAmgen's Repatha Study Shows Reduced Risk of Heart Attack, Stroke
03/14 AstraZeneca ovarian cancer drug slows disease markedly in study
03/09 Bull market turns 8 - historical facts and figures
03/08 Compare and contrast - Trump's tweets vs private comments to CEOs
More sector news : Bio Therapeutic Drugs
4-Traders Strategies on AMGEN, INC. 
2016Expectation of a turn-around
2016Big comeback of buyers
More Strategies
Latest Tweets
03:17p#Amgen awards Cocoon Biotech, Torus Therapeutics and Holobiome bench space at..
1
01:14pAmgen moves R&D jobs from HQ to Cambridge and San Francisco as rolling re..
1
01:06pAmgen moves R&D jobs from HQ to Cambridge and San Francisco as rolling re..
1
01:02pTop story Monday: UPDATED: Amgen triggers yet another revamp, moving research..
3
08:22aReport: Amgen to Relocate or Lay Off 500 Employees | San Fernando Valley Busi.. 
More tweets
Qtime:141
News from SeekingAlpha
03/27 My Favorite Biotech Takeover Play
03/27 Amgen shakes up R&D staff, 400 jobs to be cut/relocated
03/27 Karyopharm's Selinexor Should Drive Substantial Growth
03/27 AMGEN : A Compelling Price On The Latest Dip
03/24 Industry And Dark Pool Traders Bearish On Amgen
Advertisement
Chart AMGEN, INC.
Duration : Period :
Amgen, Inc. Technical Analysis Chart | AMGN | US0311621009 | 4-Traders
Full-screen chart
Technical analysis trends AMGEN, INC.
Short TermMid-TermLong Term
TrendsBearishBullishBullish
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 25
Average target price 186 $
Spread / Average Target 13%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Robert A. Bradway Chairman & Chief Executive Officer
Esteban Santos Executive Vice President-Operations
David W. Meline Chief Financial Officer & Executive Vice President
Paul R. Eisenberg Chief Medical Officer & Senior VP-Global Medical
Frank J. Biondi Independent Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
AMGEN, INC.12.79%121 448
CELGENE CORPORATION7.87%97 137
GILEAD SCIENCES, INC.-5.74%88 227
REGENERON PHARMACEUTIC..4.52%40 701
ACTELION LTD24.40%29 848
VERTEX PHARMACEUTICALS..23.25%22 558
More Results